Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, gives an overview of the findings of an ongoing Phase Ib study (NCT02942290) of venetoclax plus azacitidine for patients with treatment-naïve high-risk myelodysplastic syndromes (HR-MDS). Prof. Wei reports that 78 patients with HR-MDS have been treated on the trial thus far and comments on the safety findings. The majority of patients had venetoclax dose interruptions due to adverse events. The intention-to-treat overall response rate was 80%, with 40% of patients achieving a complete response (CR) and a median time to CR of 2.6 months. 23% of patients went on to receive allogeneic transplantation. Prof. Wei also discusses the impact of biomarkers on outcomes with this treatment regimen. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.